UK Biotech Firm Eyes Riyadh as Hub To Build Health Unicorns.

Phytome Life Sciences, a UK biotech firm, plans to establish a headquarters in Saudi Arabia to accelerate the commercialization of plant-based medicines and create new health firms valued at over $1 billion. This move aligns with Saudi Arabia's goal to become a hub for life sciences by 2030 in the Middle East and North Africa, and globally by 2040. Phytome intends to use Saudi Arabia as a hub for financing and manufacturing medicines developed in the UK, focusing initially on drugs for inflammatory bowel disease, epilepsy, and menopausal sleep disorder. The company's expansion into Saudi Arabia is supported by the Kingdom's Research Development and Innovation Authority. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)